ScholarLens Back to search
2016•Unpublished venueRequires access

Daratumumab Significantly Decreased Progression, Death for Relapsed Myeloma

Leah Lawrence

Open publisher page 0 citations

Abstract

A three-drug regimen that includes daratumumab, bortezomib, and dexamethasone may be the new standard of care for patients with relapsed or refractory multiple myeloma.

About this research paper

What this paper is about

A three-drug regimen that includes daratumumab, bortezomib, and dexamethasone may be the new standard of care for patients with relapsed or refractory multiple myeloma.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A three-drug regimen that includes daratumumab, bortezomib, and dexamethasone may be the new standard of care for patients with relapsed or refractory multiple myeloma.

Key concepts: Daratumumab, Multiple myeloma, Medicine, Internal medicine, Oncology, Bortezomib

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Daratumumab Significantly Decreased Progression, Death for Relapsed Myeloma — Research Paper | ScholarLens